Wells Fargo Upgrades Immunovant (IMVT) to Overweight

Wells Fargo analyst Chris M. Carey upgraded Immunovant (NASDAQ: IMVT) from Equal Weight to Overweight with a price target of $27.00 (from $10.00).

For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.

Shares of Immunovant closed at $17.75 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
• Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities